CEL-SCI Corporation
(NYSE Amex Equities : CVM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
Loading CVM News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.23%167.071.2%$750.72m
INCYIncyte Corporation
-0.81%140.131.7%$620.61m
GILDGilead Sciences, Inc.
-0.31%67.621.0%$592.40m
CELGCelgene Corporation
0.12%123.521.0%$512.77m
BIIBBiogen Inc.
0.05%278.021.3%$452.66m
REGNRegeneron Pharmaceuticals, Inc.
-0.44%367.502.1%$316.34m
KITEKite Pharma, Inc.
-1.98%74.8718.8%$205.97m
ALXNAlexion Pharmaceuticals, Inc.
-0.08%119.991.6%$205.63m
TSROTESARO, Inc.
-0.88%154.4116.1%$175.89m
ESPREsperion Therapeutics, Inc.
5.64%41.2118.7%$173.78m
ILMNIllumina, Inc.
0.37%168.413.7%$165.85m
AUPHAurinia Pharmaceuticals Inc.
-1.29%8.426.3%$146.85m
CLVSClovis Oncology, Inc.
0.89%67.7817.5%$142.72m
VRTXVertex Pharmaceuticals Incorporated
0.07%90.102.2%$135.05m
EXELExelixis, Inc.
0.00%20.487.0%$106.18m

Company Profile

CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against advanced primary head and neck cancer. It is also developing its pre-clinical Ligand Epitope Antigen Presentation System technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.